Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Daniel Marrero, M.D

Diagnostic Radiology Farmington, CT Male

NPI: 1265743041

Total Payments

$111,375

2022 Payments

$61,475

Companies

Transactions

Medicare Patients

5,799

Medicare Billing

$181,957

Payment Breakdown by Category

Research$111,375 (100.0%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Unspecified	$111,375	27	100.0%

Top Paying Companies

Company	Total	Records	Latest Year
Endo Pharmaceuticals Inc.	$111,375	27	$0 (2022)

Payment History by Year

Year	Amount	Transactions	Top Company
2022	$61,475	9	Endo Pharmaceuticals Inc. ($61,475)
2021	$42,850	13	Endo Pharmaceuticals Inc. ($42,850)
2020	$7,050	5	Endo Pharmaceuticals Inc. ($7,050)

All Payment Transactions

27 individual payment records from CMS Open Payments — Page 1 of 2

Date	Company	Product	Nature	Form	Amount	Type
12/21/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$5,125.00	Research
Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder)
10/19/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$852.75	Research
Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder)
10/19/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$272.25	Research
Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder)
08/10/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$21,400.00	Research
Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder)
05/10/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$10,900.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
05/10/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$7,000.00	Research
Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder)
03/08/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$3,625.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
02/08/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$7,675.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
02/08/2022	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$4,625.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
12/21/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$1,625.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
12/07/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$5,350.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
10/12/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$4,625.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
10/12/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$3,950.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
09/07/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$3,800.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
07/13/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$5,725.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
07/13/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$3,200.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
06/15/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$5,100.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
05/11/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$3,100.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
04/13/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$1,750.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
03/09/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$2,500.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
02/02/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$1,750.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
01/12/2021	Endo Pharmaceuticals Inc.	—	—	Cash or cash equivalent	$375.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER
12/15/2020	Endo Pharmaceuticals Inc.	XIAFLEX (Biological)	—	Cash or cash equivalent	$375.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER • Category: ORTHOPEDIC
11/17/2020	Endo Pharmaceuticals Inc.	XIAFLEX (Biological)	—	Cash or cash equivalent	$2,175.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER • Category: ORTHOPEDIC
10/13/2020	Endo Pharmaceuticals Inc.	XIAFLEX (Biological)	—	Cash or cash equivalent	$1,350.00	Research
Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER • Category: ORTHOPEDIC

1 2 »

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER	Endo Pharmaceuticals Inc.	$76,725	22
Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder)	Endo Pharmaceuticals Inc.	$34,650	5

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2023	41	1,508	1,667	$161,150	$46,358
2022	38	1,584	1,775	$178,130	$51,511
2021	40	1,486	1,626	$156,830	$46,853
2020	34	1,221	1,343	$120,098	$37,236

Total Patients

5,799

Total Services

6,411

Medicare Billing

$181,957

Procedure Codes

156

All Medicare Procedures & Services

156 procedure records from CMS Medicare Utilization — Page 1 of 7

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
72125	Ct scan of upper spine without contrast	Facility	2023	314	348	$45,240	$13,137	29.0%
76377	3d radiographic procedure with computerized image postprocessing	Facility	2023	72	113	$11,300	$3,463	30.6%
74177	Ct scan of abdomen and pelvis with contrast	Facility	2023	46	46	$10,120	$3,271	32.3%
72131	Ct scan of lower spine without contrast	Facility	2023	64	69	$8,625	$2,499	29.0%
70450	Ct scan head or brain without contrast	Facility	2023	76	79	$8,295	$2,485	30.0%
73721	Mri scan of leg joint without contrast	Facility	2023	35	39	$7,995	$2,079	26.0%
73700	Ct scan of leg without contrast	Facility	2023	51	53	$6,625	$2,031	30.7%
71275	Ct scan of blood vessels of chest with contrast	Facility	2023	20	20	$4,400	$1,419	32.3%
74176	Ct scan of abdomen and pelvis without contrast	Facility	2023	20	20	$4,200	$1,375	32.7%
73221	Mri scan of arm joint without contrast	Facility	2023	25	25	$5,125	$1,239	24.2%
73720	Mri scan of leg before and after contrast	Facility	2023	11	13	$3,380	$1,098	32.5%
71045	X-ray of chest, 1 view	Facility	2023	130	145	$2,900	$1,042	35.9%
72128	Ct scan of middle spine without contrast	Facility	2023	26	27	$3,375	$1,025	30.4%
20610	Aspiration and/or injection of fluid from large joint	Facility	2023	20	25	$5,600	$959.10	17.1%
73718	Mri scan of leg without contrast	Facility	2023	17	18	$3,690	$895.16	24.3%
71046	X-ray of chest, 2 views	Facility	2023	97	100	$2,500	$840.01	33.6%
71250	Ct scan of chest without contrast	Facility	2023	19	19	$2,375	$793.88	33.4%
73200	Ct scan of arm without contrast	Facility	2023	20	20	$2,500	$778.85	31.2%
73701	Ct scan of leg with contrast material	Facility	2023	13	16	$2,240	$705.48	31.5%
72132	Ct scan of lower spine with contrast	Facility	2023	13	13	$1,950	$597.32	30.6%
77002	Fluoroscopic guidance for needle placement	Facility	2023	22	27	$2,430	$581.10	23.9%
72100	X-ray of lower and sacral spine, 2-3 views	Facility	2023	48	51	$1,530	$447.00	29.2%
73564	X-ray of knee, 4 or more views	Office	2023	11	12	$1,200	$446.05	37.2%
73030	X-ray of shoulder, minimum of 2 views	Facility	2023	39	47	$1,175	$317.10	27.0%
93970	Ultrasound study of arm or leg veins with compression and maneuvers	Facility	2023	11	11	$880.00	$300.30	34.1%

1 2 3…7 »

About Dr. Daniel Marrero, M.D

Dr. Daniel Marrero, M.D is a Diagnostic Radiology healthcare provider based in Farmington, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2010. The National Provider Identifier (NPI) number assigned to this provider is 1265743041.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Marrero, M.D has received a total of $111,375 in payments from pharmaceutical and medical device companies, with $61,475 received in 2022. These payments were reported across 27 transactions from 1 company. The most common payment nature is "" ($111,375).

As a Medicare-enrolled provider, Marrero has provided services to 5,799 Medicare beneficiaries, totaling 6,411 services with total Medicare billing of $181,957. Data is available for 4 years (2020–2023), covering 156 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Diagnostic Radiology
Other Specialties Diagnostic Radiology, Diagnostic Radiology
Location Farmington, CT
Active Since 06/28/2010
Last Updated 08/02/2018
Taxonomy Code 2085R0202X
Entity Type Individual
Practice Solo Practitioner
NPI Number 1265743041

Products in Payments

XIAFLEX (Biological) $7,050

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.